Published in Lab Law Weekly, August 19th, 2005
The ongoing disruption in the company's operations caused by its product recall and the suspension of manufacturing activities has had, and will continue to have, a material adverse effect on the company's results of operations and financial position. The company intends to continue to work proactively and cooperatively with the FDA to achieve...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.